Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy

BACKGROUND: Most lethal prostate cancers progress from relapse of aggressive primary disease. Recently, the most significant advances in survival benefit from systemic therapy have come from moving the administration of therapy to an earlier disease state. There is movement toward using biomarkers f...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Eur Urol Focus
Главные авторы: VanderWeele, David J., Finney, Richard, Katayama, Kotoe, Gillard, Marc, Paner, Gladell, Imoto, Seiya, Yamaguchi, Rui, Wheeler, David, Lack, Justin, Cam, Maggie, Pontier, Andrea, Minh Nguyen, Yen Thi, Maejima, Kazuhiro, Sasaki-Oku, Aya, Nakano, Kaoru, Tanaka, Hiroko, Griend, Donald Vander, Kubo, Michiaki, Ratain, Mark J., Miyano, Satoru, Nakagawa, Hidewaki
Формат: Artigo
Язык:Inglês
Опубликовано: 2018
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6586528/
https://ncbi.nlm.nih.gov/pubmed/29398457
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.euf.2018.01.006
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы